These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 32339673)

  • 1. Relapsing cutaneous leishmaniasis in a patient requiring TNF-α-inhibitor Infliximab for Takayasu-arteritis: Case report and review of the literature.
    Heinemann M; Omansen TF; Hennigs A; Völker K; Menz A; Addo MM; Schmiedel S
    Travel Med Infect Dis; 2020; 37():101700. PubMed ID: 32339673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Infectious complications in patients treated with anti-TNF-alpha: two cases of leishmaniasis].
    Bousquet E; Mura F; Villain M; Rivière S; Konate A; Schneider C
    J Fr Ophtalmol; 2012 Nov; 35(9):695-9. PubMed ID: 22925844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumour necrosis factor-induced visceral and cutaneous leishmaniasis: case report and review of the literature.
    Català A; Roé E; Dalmau J; Pomar V; Muñoz C; Yelamos O; Puig L
    Dermatology; 2015; 230(3):204-7. PubMed ID: 25633623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leishmaniasis and tumor necrosis factor alpha antagonists in the Mediterranean basin. A switch in clinical expression.
    Bosch-Nicolau P; Ubals M; Salvador F; Sánchez-Montalvá A; Aparicio G; Erra A; Martinez de Salazar P; Sulleiro E; Molina I
    PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007708. PubMed ID: 31469834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous leishmaniasis associated with anti-tumour necrosis factor-α drugs: an emerging disease.
    Marcoval J; Penín RM; Sabé N; Valentí-Medina F; Bonfill-Ortí M; Martínez-Molina L
    Clin Exp Dermatol; 2017 Apr; 42(3):331-334. PubMed ID: 28239885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous leishmaniasis associated with TNF-α blockers: a case report.
    Nieto Gómez P; Casas Hidalgo I; Casas Hidalgo MP; Álvarez Sánchez R; Rodríguez Delgado A; Cabeza-Barrera J
    Eur J Hosp Pharm; 2019 Jul; 26(4):233-234. PubMed ID: 31338176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PKDL and other dermal lesions in HIV co-infected patients with Leishmaniasis: review of clinical presentation in relation to immune responses.
    Zijlstra EE
    PLoS Negl Trop Dis; 2014; 8(11):e3258. PubMed ID: 25412435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour Necrosis Factor-alpha (TNF-α) and its soluble receptor type 1 (sTNFR I) in human active and healed leishmaniases.
    Nateghi Rostami M; Seyyedan Jasbi E; Khamesipour A; Mohammadi AM
    Parasite Immunol; 2016 Apr; 38(4):255-60. PubMed ID: 26813918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relapsing cutaneous leishmaniasis in a patient with ankylosing spondylitis treated with infliximab.
    Mueller MC; Fleischmann E; Grunke M; Schewe S; Bogner JR; Löscher T
    Am J Trop Med Hyg; 2009 Jul; 81(1):52-4. PubMed ID: 19556566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of leishmaniasis with TNF alpha promoter and SLC11A1 gene polymorphisms in patients of two endemic areas in Mexico.
    Ortiz-Flores A; De la Rosa-López G; Zavaleta-Villa B; Chávez-López S; Pastor-Santiago J; Guzmán-Bracho C; Romero-Valdovinos M; Martínez-Hernández F; Olivo-Díaz A
    Microbes Infect; 2015 May; 17(5):387-94. PubMed ID: 25603101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoregulatory and proinflammatory cytokine production in visceral and cutaneous leishmaniasis.
    Raziuddin S; Abdalla RE; el-Awad EH; al-Janadi M
    J Infect Dis; 1994 Oct; 170(4):1037-40. PubMed ID: 7930702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrence of visceral and muco-cutaneous leishmaniasis in a patient under immunosuppressive therapy.
    Darcis G; Van der Auwera G; Giot JB; Hayette MP; Tassin F; Arrese Estrada J; Cnops L; Moutschen M; de Leval L; Leonard P
    BMC Infect Dis; 2017 Jul; 17(1):478. PubMed ID: 28687071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunodetection and molecular determination of visceral and cutaneous Leishmania infection using patients' urine.
    Mirzaei A; Ahmadipour F; Cannet A; Marty P; Delaunay P; Perrin P; Dorkeld F; Sereno D; Akhoundi M
    Infect Genet Evol; 2018 Sep; 63():257-268. PubMed ID: 29847780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma levels of tumor necrosis factor-alpha (TNF-α), TNF-α soluble receptor type 1 (sTNFR I) and IL-22 in human leishmaniasis.
    Nateghi Rostami M; Seyyedan Jasbi E; Khamesipour A; Miramin Mohammadi A
    Trop Biomed; 2015 Sep; 32(3):478-84. PubMed ID: 26695208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical aspects and management of cutaneous leishmaniasis in rheumatoid patients treated with TNF-α antagonists.
    Neumayr AL; Morizot G; Visser LG; Lockwood DN; Beck BR; Schneider S; Bellaud G; Cordoliani F; Foulet F; Laffitte EA; Buffet P; Blum JA
    Travel Med Infect Dis; 2013; 11(6):412-20. PubMed ID: 23972958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TNF-α - 308 G/A and IFN-γ + 874 A/T gene polymorphisms in Saudi patients with cutaneous leishmaniasis.
    Ahmed AA; Rasheed Z; Salem T; Al-Dhubaibi MS; Al Robaee AA; Alzolibani AA
    BMC Med Genet; 2020 May; 21(1):104. PubMed ID: 32404058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphomatoid Papulosis Type B in a Patient with Crohn's Disease Treated with TNF-Alpha Inhibitors Infliximab and Adalimumab.
    Medvecz M; Kiss N; Hársing J; Kuroli E; Hegede G; Csomor J; Kárpáti S; Marschalkó M
    Acta Dermatovenerol Croat; 2019 Sep; 27(3):202-204. PubMed ID: 31542070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Localized Cutaneous Leishmaniasis due to Leishmania infantum in a Patient Treated with Infliximab.
    Hakimi S; Rivière S; Del Giudice P; Dereure J; Le Quellec A
    Dermatology; 2010; 220(1):63-5. PubMed ID: 19907139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Visceral leishmaniasis with cutaneous symptoms in a patient treated with infliximab followed by fatal consequences.
    Juzlova K; Votrubova J; Kacerovska D; Lukas M; Bortlik M; Rohacova H; Nohynkova E; Vojackova N; Fialova J; Hercogova J
    Dermatol Ther; 2014; 27(3):131-4. PubMed ID: 24903470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leishmaniasis in immunosuppressed individuals.
    van Griensven J; Carrillo E; López-Vélez R; Lynen L; Moreno J
    Clin Microbiol Infect; 2014 Apr; 20(4):286-99. PubMed ID: 24450618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.